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Abstract
Background: We describe the risk indicators for oral mucositis (OM) in paediatric oncology
patients hospitalised in the Institut Gustave Roussy (Villejuif-Paris) and treated with alkylant
chemotherapy with autologous peripheral blood progenitor cells.
Methods: The sample was selected using PIGAS software. Three groups of subjects received
different chemotherapy regimens: A. Melphalan, B. Busulfan and C. other alkylant protocols. The
degree of mucositis was recorded by CTC version 2.0 (Common Toxicity Criteria). Descriptive
statistics were performed. The association between mucositis and risk indicator variables was
tested using a χ2 test. The association between case status and covariates was tested using
unconditional logistic regression analysis.
Results: Of the 337 children enrolled, 241 showed mucositis (group 1) and 96 did not show
mucositis (group 2) during alkylant chemotherapy. There was a higher prevalence of male patients
in both groups. The three different chemotherapy regimen groups are correlated with the
appearance of oral mucositis (χ2 = 22.42, p < 0.01). Weight loss was higher in group 1 (χ2 = 6.31,
p = 0.01). The duration of aplasia was lower in the Busulfan protocol (7.5 days) than in the
Melphalan group (9.3 days) or the other regimens (8.6 days). The use of Bufulfan® was directly
associated with case status (presence of oral mucositis): odds ratio [OR] = 2.1 and confidence
interval [95%CI] = 1.3–3.0. Also, occurrences of germinal tumours and secondary bacterial
infections were directly linked with case status: [OR] = 1.4 and 1.8, confidence interval [95%CI] =
1.2 – 1.7 and 1.1 – 2.5, respectively.
Conclusion: The presence of OM was associated with the three different chemotherapy regimens
considered; in particularly patients treated with Busulfan had the highest prevalence.
Background
Many forms of cancer can be treated effectively with radi-
otherapy and chemotherapy. However, these treatments
have significant dose-limiting toxicities. In western coun-
tries, 1 out of every 500 to 600 children develops child-
hood cancer before reaching the age of 15 years [1].
Currently, high-dose chemotherapy with autologous
peripheral blood progenitor cell transplantation is the pri-
mary treatment for tumoral lesions in children [2]. Cancer
and chemotherapy are amongst the leading health prob-
lems influencing the quality of life of the individual. The
complications of many treatment regimens appear fre-
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quently in the mouth and cause serious disturbances.
Recent investigations have demonstrated that many seri-
ous infections originate from the mouth, and anti-neo-
plastic chemotherapy or immunosuppressive drugs
increase the susceptibility of patients [3].
Oral mucositis (OM) is multifactorial in nature. The dis-
ruption or loss of rapidly dividing epithelial progenitor
cells is a trigger for the onset of the disorder. However, the
actual manifest dysfunction and its severity and duration
are greatly influenced by changes in other cell popula-
tions, immune responses and the effects of oral flora. This
toxicity frequently complicates the course of autologous
bone marrow transplantation; it causes severe pain as well
as cramping, nausea and gastro-enteritis. In addition,
food and fluid intake may be poor, the ability to absorb
nutrients much reduced and the susceptibility to infection
greatly increased. The nature and degree of mucositis
experienced by a patient varies according to the treatment
regimen applied (combination of radiotherapy and chem-
otherapy, dosage, duration and sequence). Mucositis can
therefore result in under-nutrition and significantly
decreases a patient's quality of life. Modulation of the
treatment regimen (use of lower doses or long recovery
intervals between doses) remains the most effective
means of limiting the actual incidence and severity. This
event can therefore compromise patient prognosis [4].
Mucositis is an iatrogenic stomatitis that usually begins
with aplasia, between 7 and 14 days after the initiation of
chemotherapy. During the subsequent 1–2 weeks there is
a loss of epithelial structure and integrity and severe ulcer-
ation develops. Much of this damage occurs in non-kerat-
inized areas such as the cheeks, underside of the tongue
and floor of the mouth. The epithelium of the oral cavity
and of the digestive tract can renew rapidly, making their
cells highly sensitive to the cytotoxic effects of chemother-
apy. Mucosal lesions are only temporary. They are caused
by the lowering of the renewal rate of the basal epithe-
lium, leading to the thinning, denudation and ulceration
of the soft tissue of the digestive system [5]. Epithelial
denudation and mucosal damage may persist for 2–4
weeks after the cessation of radiotherapy [6]. The patho-
physiology of this condition is still undefined, but
recently the hypothesis has been put forward that mucosi-
tis is the result of a complex interaction of factors occur-
ring in different phases [7].
All the regimens used in the Department of Paediatric
Oncology of the Institut Gustave Roussy include alkylat-
ing agents. These agents are currently the most effective
and frequently-used antineoplastic agents for treating pae-
diatric cancers such as cerebral tumours (medulloblast-
oma, neuroblastoma) and other solid tumours such as
osteosarcoma. They form covalent links with DNA. This
may explain the anticarcinogenic power and cytotoxicity
of these drugs. The effects on DNA are most marked in
cells with a high mitotic index, including the proliferating
tissues of the bone marrow and the lining of the gastroin-
testinal tract.
The aim of the present investigation was to identify risk
indicators and side effects of oral mucositis in a paediatric
population receiving alkylant chemotherapy. It is impor-
tant to describe factors that affect mucositis in order to
reduce the frequency of this side effect and to improve the
quality of life of patients.
Methods
Study design
This study was designed as a retrospective cross-sectional
case-control study. The study was approved by the Ethical
Committee of the University of Sassari, Italy (n° 508/
2004). The sample consisted of a paediatric oncology
population from 1 to 15 years old, hospitalized in the
Paediatrics Department ("La Mer") of the IGR from June
1992 to June 2003; during this period 453 subjects were
examined. All patients were treated by HDC containing at
least one alkylant drug in the protocol, followed by autol-
ogous stem cell transplantation and then by supplemen-
tation with granulocyte colony-stimulating factor. They
all received conventional chemotherapy, either at diagno-
sis or at relapse or both, in accordance with on-going
European Society for Medical Oncology protocols [8]. The
conditioning regimens were categorised into three groups
on the basis of the principal drug included in the protocol
(Melphalan, Busulfan, other alkylant drug). During treat-
ment, the patients underwent a standardized oral care reg-
imen: mouthwashes twice a day throughout the
treatment. Exclusion criteria included age greater than 15
years (72 patients), previous radiotherapy (36 subjects) or
more than 2 autografts (8 subjects). If two bone marrow
transplantations had occurred, only the first was consid-
ered.
Methods
Patients' data were collected by the nursing and medical
staff of IGR, transcribed on to standard forms, then
entered on a database managed with PIGAS (Gustave
Roussy Institute, Villejuif, France) [9]. The autologous
stem cell transplantation conditioning regimens and sup-
portive care regimens remained the same throughout the
10 years of data collection. OM was graded by the Com-
mon Toxicity Criteria (CTC) version 2.0 of the National
Cancer Institute [10] as shown in Table 1. In this study,
only grades greater than 1 were considered in relation to
mucositis.
The sample was divided in two groups: children with
(cases) and without (controls) oral mucositis. Gender andBMC Oral Health 2006, 6:13 http://www.biomedcentral.com/1472-6831/6/13
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age were recorded at diagnosis and at the time of autolo-
gous stem cell transplantation. All children in the sample
received HDC including at least one alkylant drug, and on
this basis were divided into three groups: treated with
Melphalan, with Busulfan, or with other alkylant agent.
Aplasia was defined as a white blood cell count < 500/
mm3, red corpuscle count < 2,5 × 106/mm3 and platelets
< 20000/mm3. The duration of aplasia was recorded.
Children were weighed on calibrated weighing scales and
percentage weight loss was calculated. Viral and bacterial
infections were diagnosed using cotton-tipped sterile
swabs. Grades of vomiting, diarrhoea and anorexia were
scored by the NCI/SIOP quotation system. Finally, nerv-
ous central system problems and haemorrhage were
recorded (Table 2).
Statistical methods
STATA statistical data analysis software (Version 8.2, Stata
Corporation, College Station, Texas USA) was used. Ini-
tially, clinical condition parameters and potential risk
indicators were analysed univariately to describe the vari-
ables and distributions. Student's t test was used to com-
pare the two groups, and p < 0.05 was taken as the
criterion of significance. To avoid the attenuating effect of
unequal variability among groups on the value of t, a
square root transformation was performed when the
response variable was a count. For categorical variables,
difference between groups (1 and 2) was evaluated by χ2
test or Fischer's exact test.
Possible associations of cases (patients with oral mucosi-
tis) or controls (patients without oral mucositis) with
treatment regimen, aplasia and other variables were ana-
lysed using unconditional logistic regression analysis.
Covariates resulted statistically significant in bivariate
analysis entered in the logistic regression.
Results
There were 337 patients in the analytical sample (213
boys and 124 girls): 241 in the case group (with mucosi-
tis, grade > 1) and 96 in the control group (without
mucositis, grade ≤ 1). The mean age was 7.6 years at the
time of diagnosis and 8.9 years at the time of autologous
stem cell transplantation. Table 2 describes the character-
istics of the patients included in this study and their treat-
ments. There was a higher prevalence of male patients in
both groups (χ2 = 2.50, p = 0.11). Tumours were divided
into five groups: cerebral tumours (CT) (n = 97, 28.8%),
germinal tumours (n = 100, 29.7% including neuroblast-
oma, nephroblastoma and retinoblastoma), sarcoma (n =
104, 30.9% including osteosarcoma, Ewing's sarcoma and
rhabdomyosarcoma), Hodgkin tumours (n = 20, 5.9%
including Hodgkin disease and non-Hodgkin lymphoma)
and miscellaneous (n = 12, 3.6%). Most of the tumoral
pathologies were correlated with expression of oral
mucositis (χ2 = 13.46, p < 0.01), especially embryonic car-
cinoma (100%), nephroblastoma (100%) and neuroblas-
toma (75.3%). The mean ages at the times of diagnosis
(7.6 ± 5.4 years for group 1 and 7.5 ± 5.6 years for group
2, t = -0.06, p = 0.84) and autologous stem cell transplan-
tation (9.2 ± 6.9 years for group 1 and 8.8 ± 6.3 years for
group 2, t = -0.21, p = 0.95) were similar in both groups
(data not in tables).
The three different chemotherapy regimens were associ-
ated with the appearance of oral mucositis (χ2 = 22.42, p
< 0.01). The patients treated with Busulfan had the high-
est prevalence of mucositis (153 subjects, 63.5%). The
association of various predictor variables with the conse-
quences of oral mucositis is shown in Table 3. Weight loss
was higher in group 1 and lower in the other group (χ2 =
6.31, p = 0.01). Anorexia was present more frequently in
patients who developed mucositis, i.e. anorexia grade
three was observed in 115 subjects with mucositis versus
12 without mucositis (χ2  = 68.01, p  < 0.001). Most
patients (83.2% in group 1 and 89.5% in group 2) did not
develop viral infections during the treatment (χ2 = 2.09, p
= 0.10), while bacterial infections were noticed in 97.8%
of the subjects in group 1 and 81.3% in group 2 (χ2 =
29.93, p < 0.01). The occurrence of vomiting was higher in
group 1 and considerably lower in group 2 (χ2 = 31.73, p
< 0.001). Cerebral nervous system complications and
haemorrhage were not associated with the occurrence of
OM (χ2 = 1.69, p = 0.19 and χ2 = 2.09, p = 0.15, respec-
tively). The mean duration of aplasia was 8.4 days in
group 1 and 7.4 days in group 2 (t = -2.27 p = 0.02). Three
members of the first group did not report these data,
therefore the analysis was performed on 334 patients. The
Table 1: Common Toxicity Criteria (CTC) version 2.0
Grade 0 No mucositis
Grade 1 Painless ulcers, erythema, or mild soreness in the absence of lesions
Grade 2 Painful erythema, oedema or ulcers, ability to eat solid
Grade 3 Painful erythema, oedema, or ulcers preventing swallowing or requiring hydration or parenteral (or enteral) nutritional support
Grade 4 Impossible to swallowBMC Oral Health 2006, 6:13 http://www.biomedcentral.com/1472-6831/6/13
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duration of aplasia estimated in relation to the three dif-
ferent chemotherapy regimens (334 children) is displayed
in figure 1. It was lower in the Busulfan protocol (7.5
days); in the other chemotherapies the durations were 9.3
days (Melphalan) and 8.6 days (other conditioning regi-
mens).
Table 4 presents the crude odds ratio (OR) estimates and
the associated 95% confidence intervals for the associa-
tion between case status (presence of oral mucositis) and
the covariates examined. The use of Bufulfan® was directly
associated with the case status (presence of oral mucosi-
tis): [OR] = 2.1 and confidence interval [95%CI] = 1.3–
3.0. Also, occurrences of germinal tumours and secondary
bacterial infections were directly linked with the case sta-
tus: [OR] = 1.4 and 1.8, confidence interval [95%CI] = 1.2
– 1.7 and 1.1 – 2.5, respectively.
Discussion
In this retrospective analysis of 337 children treated with
alkylant chemotherapy and autologous BMT, a considera-
ble percentage of the patients experienced OM during
treatment (group 1). The prevalence of oral mucositis is
estimated to range from 30% to 99% [4,11-14]. However,
most research into OM has been conducted on adult pop-
ulations with few data on young populations, and for that
reason we focused our attention on a paediatric group.
Risk factors have not been clearly identified. Potential risk
factors include genetic polymorphisms, gender, body
mass, pre-existing oral condition, quantitative and quali-
tative salivary alterations and mechanical trauma induced
by mastication [4,15]. Our study confirms that mucositis
may be an underestimated complication in an oncologi-
cal paediatric population. Gender and age were not iden-
tified as risk factor for OM; nevertheless, some previous
studies have indicated that the female gender constitutes
a significant factor risk for OM [16-18].
A systematic review of the research literature identified a
vast number of interventions that have been evaluated for
the prevention or treatment of oral mucositis in cancer
patients. However, it is obvious that many interventions
used in clinical practice have never been rigorously evalu-
ated. Furthermore, many combinations of agents are
advocated by local experts without evidence to support
their use. Combining results from different studies during
Table 2: Characteristics of cancer chemotherapy patients receiving alkylant agents
Gender
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Male 146 (60.5) 67 (69.7)
Female 95 (39.5) 29 (30.3)
χ2 Mantel-Haenszel = 2.50 p = 0.11
Diagnosis
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Cerebral tumors 70 (30.7) 27 (28.1)
Germinal tumors 78 (32.4) 22 (22.9)
Sarcoma 68 (28.2) 36 (37.5)
Hodgkin 9 (3.7) 11 (11.5)
Other 12 (5.0) - (--)
χ2 = 13.46 p < 0.01
Chemotherapy Regimens
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Melphalan® 24 (9.9) 20 (20.8)
Busulfan® 153 (63.5) 34 (35.4)
Other 64 (26.6) 42 (43.8)
χ2 = 22.42 p < 0.001BMC Oral Health 2006, 6:13 http://www.biomedcentral.com/1472-6831/6/13
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Table 3: Experience of oral mucositis by risk indicators as count (percentage) weight loss
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Yes 142 (58.9) 43 (44.8)
No 95 (39.5) 53 (55.2)
χ2 Mantel-Haenszel = 6.31 p = 0.01
Anorexia
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Grade 0 5 (2.1) 14 (14.6)
Grade 1 22 (9.1) 31 (32.3)
Grade 2 99 (41.1) 32 (33.3)
Grade 3 115 (47.7) 12 (12.5)
χ2 = 68.01 p < 0.001
Viral infections
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Yes 40 (16.8) 10 (10.5)
No 198 (83.2) 85 (89.5)
χ2 Mantel-Haenszel = 2.09 p = 0.15
Bacterial infections
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Yes 236 (97.8) 78 (81.3)BMC Oral Health 2006, 6:13 http://www.biomedcentral.com/1472-6831/6/13
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No 5 (2.1) 18 (18.8)
χ2 Mantel-Haenszel = 29.93 p < 0.001
Vomiting
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Grade 0 36 (14.9) 33 (34.4)
Grade 1 60 (24.9) 31 (32.3)
Grade 2 99 (41.1) 16 (16.7)
Grade 3 46 (19.1) 8 (8.3)
χ2 = 31.73 p < 0.001
Central nervous system complications
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Yes 23 (9.5) 5 (5.2)
No 218 (90.5) 91 (94.8)
χ2 Mantel-Haenszel = 1.69 p = 0.19
Haemmorhage
Group 1 (mucositis) n = 241 n (%) Group 2 (no mucositis) n = 96 n (%)
Yes 34 (14.1) 8 (8.3)
No 207 (85.9) 88 (91.7)
χ2 Mantel-Haenszel = 2.09 p = 0.15
Table 3: Experience of oral mucositis by risk indicators as count (percentage) weight loss (Continued)BMC Oral Health 2006, 6:13 http://www.biomedcentral.com/1472-6831/6/13
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the systematic review and meta-analysis was limited,
mostly because of differences among the study partici-
pants, interventions, and the timing and method of meas-
uring outcomes. While many interventions used for
treating or preventing mucositis have some evidence to
support their use, no intervention has been conclusively
validated by research [19,20].
Our results showed that almost every tumoral pathology
is associated with evidence of OM except for rhabdomy-
osarcoma.
Most articles suggest a difference in severity grading
between OM during chemotherapy and OM in the course
of radiotherapy [21-23]. In our sample, the three groups
of alkylating agents (with Melphalan, with Busulfan and
with other drugs) were differently related to the manifes-
tation of OM: the Busulfan regimen was associated with a
greater risk of oral mucositis than the other alkylant
agents. Several articles discuss the incidence and gravity of
OM during alkylant regimens. Wardley and co-workers
[4] reported that Melphalan protocols (High Dose Mel-
phalan and High Dose Melphalan-Total Body Irradiation)
and regimens involving Busulfan were associated with a
grave mucositis (grade 3, WHO). No subject enrolled in
our survey underwent total body irradiation. Rapoport
and co-workers [24] indicated that Busulfan protocols
may cause more severe OM then the others regimens.
The duration of aplasia was statistically lower in the
affected group. Some studies [24,25] have reported an
association between white cells and OM and confirmed
the presence of white cells in the pathogenesis of mucosi-
tis. Other investigators [4] failed to find a statistically sig-
nificant relationship between stomatitis and aplasia.
Interestingly, we observed a shorter duration of aplasia in
Busulfan regimens than in Melphalan protocols (or in the
other chemotherapies). Our result may seem contradic-
tory because the Busulfan protocol led to a higher percent-
age of stomatitis. Probable explanations of this
inconsistency are:
1) the increased duration of aplasia in the Melphalan reg-
imens (9.3 days) was caused by the use of VP-Carbo-
Melph, a very strong chemotherapy protocol;
2) prolongation of the period of aplasia in alkylant regi-
mens other than Melphalan or Busufan was attributable
to the high frequency of patients with an osteosarcoma
diagnosis treated with Tiothepa at a dose of 900 mg/m2;
osteosarcoma patients do not accept bone marrow trans-
plants very well, and this has a negative effect on the
reduction of the duration of aplasia.
The diminution of the period of aplasia in the Busulfan
protocol results from the proportionate augmentation of
the duration in the other chemotherapy treatments.
We also investigated the relationship between the appear-
ance of OM and other side effects of chemotherapy. Sto-
matitis has a statistically significant relationship with
weight loss, anorexia, vomiting and bacterial infections.
Each of the above-mentioned complications is a direct
consequence of OM (weight loss and anorexia), or is
related to a direct or indirect mucosal toxicity of the chem-
otherapy (vomiting and bacterial infections).
Conclusion
We observed that the presence of OM was associated with
the three different chemotherapy regimens considered; in
particularly patients treated with Busulfan had the highest
prevalence. We therefore propose as far as possible to
decrease the use of Busulfan for treating paediatric cancers
and to encourage the use of other chemotherapy regimens
to improve patients' quality of life.
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